316 related articles for article (PubMed ID: 18434646)
1. Contaminated heparin associated with adverse clinical events and activation of the contact system.
Kishimoto TK; Viswanathan K; Ganguly T; Elankumaran S; Smith S; Pelzer K; Lansing JC; Sriranganathan N; Zhao G; Galcheva-Gargova Z; Al-Hakim A; Bailey GS; Fraser B; Roy S; Rogers-Cotrone T; Buhse L; Whary M; Fox J; Nasr M; Dal Pan GJ; Shriver Z; Langer RS; Venkataraman G; Austen KF; Woodcock J; Sasisekharan R
N Engl J Med; 2008 Jun; 358(23):2457-67. PubMed ID: 18434646
[TBL] [Abstract][Full Text] [Related]
2. Heparin comes clean.
Schwartz LB
N Engl J Med; 2008 Jun; 358(23):2505-9. PubMed ID: 18525048
[No Abstract] [Full Text] [Related]
3. Structure elucidation and biological activity of the oversulfated chondroitin sulfate contaminant in Baxter heparin.
McKee J; Bairstow S; Szabo C; Ray J; Wielgos T; Hu P; Chess E; Nordhaus M; Hai T; Campbell J; Donovan S; Viseux N; Riedel N; Cammack J; Johnson R
J Clin Pharmacol; 2010 Oct; 50(10):1159-70. PubMed ID: 20147614
[TBL] [Abstract][Full Text] [Related]
4. Heparin-induced anaphylactic and anaphylactoid reactions: two distinct but overlapping syndromes.
Warkentin TE; Greinacher A
Expert Opin Drug Saf; 2009 Mar; 8(2):129-44. PubMed ID: 19309242
[TBL] [Abstract][Full Text] [Related]
5. Oversulfated chondroitin sulfate and OSCS-contaminated heparin cause dose- and route-dependent hemodynamic effects in the rat.
Corbier A; Le Berre N; Rampe D; Meng H; Lorenz M; Vicat P; Potdevin S; Doubovetzky M
Toxicol Sci; 2011 Jun; 121(2):417-27. PubMed ID: 21436127
[TBL] [Abstract][Full Text] [Related]
6. Contaminated heparin.
Kakkar AK; Bonnefoi M
N Engl J Med; 2008 Sep; 359(12):1292-3; author reply 1293. PubMed ID: 18810795
[No Abstract] [Full Text] [Related]
7. [Anaphylactoid reactions associated with contaminated heparin from China].
Montpas N; Désormeaux A; Keire D; Adam A
Ann Pharm Fr; 2011 Sep; 69(5):258-64. PubMed ID: 21924126
[TBL] [Abstract][Full Text] [Related]
8. Bradykinin forming capacity of oversulfated chondroitin sulfate contaminated heparin in vitro.
Adam A; Montpas N; Keire D; Désormeaux A; Brown NJ; Marceau F; Westenberger B
Biomaterials; 2010 Aug; 31(22):5741-8. PubMed ID: 20427081
[TBL] [Abstract][Full Text] [Related]
9. The effect of increasing the sulfation level of chondroitin sulfate on anticoagulant specific activity and activation of the kinin system.
Hogwood J; Naggi A; Torri G; Page C; Rigsby P; Mulloy B; Gray E
PLoS One; 2018; 13(3):e0193482. PubMed ID: 29494632
[TBL] [Abstract][Full Text] [Related]
10. [Artificial polysaccharide in contaminated heparin. Acute hypersensitivity reactions explained--but how could it happen?].
Lindahl U
Lakartidningen; 2008 Sep 24-30; 105(39):2660-1. PubMed ID: 18846871
[No Abstract] [Full Text] [Related]
11. Oversulfated chondroitin sulfate inhibits the complement classical pathway by potentiating C1 inhibitor.
Zhou ZH; Rajabi M; Chen T; Karnaukhova E; Kozlowski S
PLoS One; 2012; 7(10):e47296. PubMed ID: 23077587
[TBL] [Abstract][Full Text] [Related]
12. The tainted heparin story: an update.
Guerrini M; Shriver Z; Bisio A; Naggi A; Casu B; Sasisekharan R; Torri G
Thromb Haemost; 2009 Nov; 102(5):907-11. PubMed ID: 19888527
[TBL] [Abstract][Full Text] [Related]
13. Outbreak of adverse reactions associated with contaminated heparin.
Blossom DB; Kallen AJ; Patel PR; Elward A; Robinson L; Gao G; Langer R; Perkins KM; Jaeger JL; Kurkjian KM; Jones M; Schillie SF; Shehab N; Ketterer D; Venkataraman G; Kishimoto TK; Shriver Z; McMahon AW; Austen KF; Kozlowski S; Srinivasan A; Turabelidze G; Gould CV; Arduino MJ; Sasisekharan R
N Engl J Med; 2008 Dec; 359(25):2674-84. PubMed ID: 19052120
[TBL] [Abstract][Full Text] [Related]
14. Identification of a simple and sensitive microplate method for the detection of oversulfated chondroitin sulfate in heparin products.
Bairstow S; McKee J; Nordhaus M; Johnson R
Anal Biochem; 2009 May; 388(2):317-21. PubMed ID: 19289093
[TBL] [Abstract][Full Text] [Related]
15. Complement C1 esterase inhibitor levels linked to infections and contaminated heparin-associated adverse events.
Zhou ZH; Chen T; Arora K; Hyams K; Kozlowski S
PLoS One; 2012; 7(4):e34978. PubMed ID: 22514695
[TBL] [Abstract][Full Text] [Related]
16. Review: contaminants in heparin: review of the literature, molecular profiling, and clinical implications.
Ramacciotti E; Clark M; Sadeghi N; Hoppensteadt D; Thethi I; Gomes M; Fareed J
Clin Appl Thromb Hemost; 2011 Apr; 17(2):126-35. PubMed ID: 21288929
[TBL] [Abstract][Full Text] [Related]
17. Oversulfated chondroitin sulfate interaction with heparin-binding proteins: new insights into adverse reactions from contaminated heparins.
Li B; Suwan J; Martin JG; Zhang F; Zhang Z; Hoppensteadt D; Clark M; Fareed J; Linhardt RJ
Biochem Pharmacol; 2009 Aug; 78(3):292-300. PubMed ID: 19389385
[TBL] [Abstract][Full Text] [Related]
18. Characterization of currently marketed heparin products: adverse event relevant bioassays.
Sommers CD; Montpas N; Adam A; Keire DA
J Pharm Biomed Anal; 2012; 67-68():28-35. PubMed ID: 22591805
[TBL] [Abstract][Full Text] [Related]
19. From crisis to opportunity: a perspective on the heparin crisis.
Sasisekharan R; Shriver Z
Thromb Haemost; 2009 Nov; 102(5):854-8. PubMed ID: 19888519
[No Abstract] [Full Text] [Related]
20. Contaminated heparin.
Greinacher A; Warkentin TE
N Engl J Med; 2008 Sep; 359(12):1291-2; author reply 1293. PubMed ID: 18799565
[No Abstract] [Full Text] [Related]
[Next] [New Search]
